Dyadic International, Inc. (DYAI)

Market Cap	41.22M
Revenue (ttm)	3.50M
Net Income (ttm)	-5.81M
Shares Out	30.09M
EPS (ttm)	-0.20
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	23,539
Open	1.343
Previous Close	1.350
Day's Range	1.300 - 1.380
52-Week Range	0.930 - 2.670
Beta	0.95
Analysts	Strong Buy
Price Target	6.00 (+337.96%)
Earnings Date	Mar 26, 2025

About DYAI

Dyadic International, Inc., a biotechnology platform company, develops, produces, and sells enzymes and other proteins in the United States and internationally. It utilizes C1-cell protein production platform based on an industrially proven microorganism (C1) for the development and production of biologic products including enzymes and other proteins for human and animal health. The company offers DYAI-100, SARS-CoV-2-RBD antigen vaccine candidate towards a first-in-human Phase 1 clinical trial to demonstrate the safety in humans of a protein p...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: Nov 5, 2004
• Employees: 7
• Stock Exchange: NASDAQ
• Ticker Symbol: DYAI
• Website: https://www.dyadic.com

Financial Performance

In 2024, Dyadic International's revenue was $3.50 million, an increase of 20.58% compared to the previous year's $2.90 million. Losses were -$5.81 million, -14.51% less than in 2023.

Analyst Forecast

According to one analyst, the rating for DYAI stock is "Strong Buy" and the 12-month stock price forecast is $6.0.

Price Target

$6.0

(337.96% upside)

Analyst Consensus: Strong Buy